Advanced glycation end products decrease mesangial cell MMP-7: A role in matrix accumulation in diabetic nephropathy?

Kidney International

Volumn 72, Issue 4, 2007, Pages 481-488

  McLennan, S V ^a,b   Kelly, D J ^c   Schache, M ^d   Waltham, M ^c,d   Dy, V ^a   Langham, R G ^c   Yue, D K ^a,b   Gilbert, R E ^c,e  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Advanced glycation end product; Diabetic nephropathy; Extracellular matrix; Fibronectin; Mesangial cells

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; MATRILYSIN; STREPTOZOCIN; STROMELYSIN; STROMELYSIN 2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME DEGRADATION; ENZYME INACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MESANGIUM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; STREPTOZOCIN DIABETES;

ADULT; ANIMALS; ANTIBODIES; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOWN-REGULATION; FEMALE; FIBRONECTINS; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS; MALE; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 7; MESANGIAL CELLS; MIDDLE AGED; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 34547814720     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002357     Document Type: Article

References (39)

1. Mauer SM. Structural-functional correlations of diabetic nephropathy. Kidney Int 1994; 45: 612-622.
2. McLennan SV, Fisher EJ, Yue DK et al. High glucose concentration causes a decrease in mesangium degradation. Diabetes 1994; 43: 1041-1045.
3. McLennan SV, Martell SK, Yue DK. Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy. Diabetes 2002; 51: 2612-2618.
4. Williamson JR, Kilo C. Basement-membrane thickening and diabetic microangiopathy. Diabetes 1976; 25: 925-927.
5. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007; 292: F905-F911.
6. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
7. Soulis-Liparota T, Cooper M, Papazoglou D et al. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328-1334.
8. Soulis T, Cooper ME, Vranes D et al. The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment. Kidney Int 1996; 50: 627-634.
9. Kelly DJ, Gilbert RE, Cox AJ et al. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001; 12: 2098-2107.
10. Sharma K, Ziyadeh FN. The emerging role of transforming growth factorb in kidney diseases. Am J Physiol 1994; 266: F829-F842.
11. Border WA, Noble NA. Transforming growth factor-β in tissue fibrosis. New Engl J Med 1994; 331: 1286-1392.
12. Overall CM, Wrana JL, Sodek J. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 1991; 266: 14064-14071.
13. Kerr LD, Miller DB, Matrisian LM. TGF-beta 1 inhibition of transin/ stromelysin gene expression is mediated through a Fos binding sequence. Cell 1990; 61: 267-278.
14. Bruner KL, Rodgers WH, Gold LI et al. Transforming growth factor beta mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium. Proc Natl Acad Sci USA 1995; 92: 7362-7366.
15. Mauer S, Steffes M, Ellis E et al. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984; 74: 1143-1155.
16. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999; 56: 1627-1637.
17. Nagase H. Matrix metalloproteinases - a mini review. In: Koide H, Hayashi T (eds). Extracellular Matrix in the Kidney, vol 107. Karger, Basel, 1994, pp 85-93.
18. Nakamura T, Fukui M, Ebihara I et al. Abnormal gene expression of matrix metalloproteinases and their inhibitors in glomeruli from diabetic rats. Renal Physiol Biochem 1994; 17: 316-325.
19. McLennan SV, Yue DK, Turtle JR. Effect of glucose on matrix metalloproteinase activity in mesangial cells. Nephron 1998; 79: 293-298.
20. McLennan SV, Kelly DJ, Cox AJ et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002; 45: 268-275.
21. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. New Engl J Med 1988; 318: 1315-1321.
22. Jerums G, Allen TJ, Campbell DJ et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 2001; 37: 890-899.
23. Soulis T, Thallas V, Youssef S et al. Advanced glycation end products and the receptor for advanced glycated end products co-localise in organs susceptible to diabetic microvascular injury: immunohistochemical studies. Diabetologia 1997; 40: 619-628.
24. Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir Res 2001; 2: 10-19.
25. Parks WC, Lopez-Boado YS, Wilson CL. Matrilysin in epithelial repair and defense. Chest 2001; 120: 36S-41S.
26. Surendran K, Simon TC, Liapis H et al. Matrilysin (MMP-7) expression in renal tubular damage: association with Wnt4. Kidney Int 2004; 65: 2212-2222.
27. Abdel Wahab N, Mason RM. Modulation of neutral protease expression in human mesangial cells by hyperglycaemic culture. Biochem J 1996; 20(Part 3): 777-783.
28. Falk RJ, Scheinman JI, Mauer SM et al. Polyantigenic expansion of basement membrane constituents in diabetic nephropathy. Diabetes 1983; 32(Suppl 2): 34-39.
29. Nerlich A, Schleicher E. Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions. Am J Pathol 1991; 139: 889-899.
30. Ziyadeh FN, Hoffman BB, Han DC et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice [see comments]. Proc Natl Acad Sci USA 2000; 97: 8015-8020.
31. Yamamoto T, Nakamura T, Noble NA et al. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993; 90: 1814-1818.
32. Ziyadeh FN, Sharma K, Ericksen M et al. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J Clin Invest 1994; 93: 536-542.
33. Shankland SJ, Scholey JW, Ly H et al. Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Kidney Int 1994; 46: 430-442.
34. Gilbert RE, Cox A, Wu LL et al. Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of angiotensin converting enzyme inhibition. Diabetes 1998; 47: 414-422.
35. Iwano M, Kubo A, Nishino T et al. Quantification of glomerular TGF-beta-1 mRNA in patients with diabetes mellitus. Kidney Int 1996; 49: 1120-1126.
36. Yamagishi S, Inagaki Y, Okamoto T et al. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 2003; 63: 464-473.
37. Booth AA, Khalifah RG, Todd P et al. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem 1997; 272: 5430-5437.
38. Kislinger T, Fu C, Huber B et al. N({epsilon})-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274: 31740-31749.
39. Langham RG, Kelly DJ, Gow RM et al. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 2004; 44: 826-831.